Brivanib (BMS) fails Phase III trial for Hepatocellular Carcinoma

Bristol Myers Squibb (BMS) announced the results of the phase III BRISK-FL clinical trial of the investigational agent brivanib versus sorafenib as first-line treatment in patients with advanced Hepatocellular Carcinoma (liver cancer). The study did not meet its primary overall survival objective based upon a non-inferiority statistical design. BMS is considering options for the ongoing brivanib development program. Ongoing clinical trials of brivanib, which include Hepatocellular Carcinoma as well as other tumor types, will continue at the present time.